Vimarsana
Biggest News Aggregation in the World

Page 3 - John Mendlein News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from John Mendlein. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In John Mendlein Today - Breaking & Trending Today

Fate Therapeutics (NASDAQ:FATE) Rating Lowered to Sell at StockNews.com - Vimarsana News

Fate Therapeutics (NASDAQ:FATE) Rating Lowered to Sell at StockNews.com

Fate Therapeutics (NASDAQ:FATE – Get Rating) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Tuesday. Other research analysts have also recently issued reports about the company. BMO Capital Markets cut Fate Therapeutics from an “outperform” rating to a “market perform” rating and lowered […]

Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Up 15.6% in March - Vimarsana News

Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Up 15.6% in March

Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 21,580,000 shares, a growth of 15.6% from the February 28th total of 18,660,000 shares. Based on an average daily trading volume, of 4,010,000 shares, […]

Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Up 15.6% in March - Vimarsana News

Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Up 15.6% in March

Should You Buy or Sell Fate Therapeutics Stock? Get The Latest FATE Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Rating of "Hold" from Brokerages - Vimarsana News

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Rating of "Hold" from Brokerages

Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) has been assigned an average recommendation of “Hold” from the twenty-three brokerages that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and six have assigned a buy rating to the company. The […]

Fate Therapeutics (NASDAQ:FATE) Stock Rating Upgraded by StockNews.com - Vimarsana News

Fate Therapeutics (NASDAQ:FATE) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Fate Therapeutics (NASDAQ:FATE – Get Rating) from a sell rating to a hold rating in a research report released on Monday. Other equities research analysts also recently issued reports about the stock. SVB Leerink dropped their price objective on shares of Fate Therapeutics from $62.00 to $10.00 and set an outperform […]